Table of Contents
1 INDUSTRY OUTLOOK 9
1.1 Industry overview 10
1.2 Total addressable market 10
1.3 Industry Trends 11
2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 12
2.3 Research Methodology 12
2.4 Report Assumptions 13
3 Market Snapshot 14
3.1 Market Definition - Infoholic Research 14
3.2 Advantages of Point-of-care testing 14
3.3 Disadvantages of Point-of-care testing 14
3.4 Segmented Addressable Market (SAM) 14
3.5 Trends of the point-of-Care diagnostics market 15
3.6 Related Markets 16
3.6.1 Molecular diagnostics 16
3.6.2 Infectious disease diagnostics 16
4 Market Outlook 16
4.1 Overview 16
4.2 Funding scenario 17
4.3 Market segmentation 19
4.4 PEST Analysis 19
4.5 Porter 5(Five) Forces 21
5 Market Characteristics 22
5.1 DRO - Global Point-of-care Diagnostics Market Dynamics 22
5.1.1 Drivers 22
5.1.1.1 Increasing prevalence of infectious disease 22
5.1.1.2 Growing incidence of life-style disease 23
5.1.1.3 Technological innovations 23
5.1.1.4 Increasing adoption of point-of-care diagnostics 24
5.1.2 Opportunities 24
5.1.2.1 Growth opportunities in emerging markets 24
5.1.2.2 Increasing awareness towards point-of-care diagnostics in developing countries 25
5.1.3 Restraints 25
5.1.3.1 Stringent approval process 25
5.1.3.2 Product recalls 26
5.1.3.3 Unfavorable reimbursement scenario 26
6 Product: Market Size and Analysis 29
6.1 Overview 29
6.2 Glucose monitoring kits 31
6.3 Infectious disease testing kits 32
6.4 Pregnancy and fertility testing kits 33
6.5 Hematology testing kits 35
6.6 Cardiometabolic monitoring kits 35
6.7 Urinalysis testing kits 37
6.8 Coagulation monitoring kits 38
6.9 Tumour or cancer marker testing kits 39
6.10 Cholesterol testing kits 40
6.11 Drugs of abuse testing kits 40
6.12 Others 41
7 Prescription mode: Market Size and Analysis 42
7.1 Overview 42
7.2 Prescription-based point-of-care diagnostics 44
7.3 Over the counter-based point-of-care diagnostics 45
8 End Users: Market Size and Analysis 46
8.1 Overview 46
8.2 Hospitals 47
8.3 Clinics 47
8.4 Home-care 48
8.5 Others 48
9 Regions: Market Size and Analysis 49
9.1 Overview 49
9.2 North America 50
9.2.1 Overview 50
9.2.2 US 51
9.2.3 Canada 52
9.3 Europe 52
9.3.1 Overview 52
9.3.2 UK 53
9.3.3 Germany 53
9.3.4 France 54
9.3.5 Spain 54
9.4 APAC 54
9.4.1 Overview 54
9.4.2 India 55
9.4.3 China 56
9.5 Rest of the World 56
10 Competitive Landscape 57
10.1 Overview 57
11 Vendor Profiles 61
11.1 Abbott Laboratories 61
11.1.1 Overview 61
11.1.2 Business Unit 64
11.1.3 Geographic Presence 65
11.1.4 Business Focus 66
11.1.5 SWOT Analysis 67
11.1.6 Business Strategy 67
11.2 F.Hoffmann-La Roche Ltd 68
11.2.1 Overview 68
11.2.2 Business Unit 71
11.2.3 Geographic Presence 72
11.2.4 Business Focus 73
11.2.5 SWOT Analysis 73
11.2.6 Business Strategy 74
11.3 Johnson & Johnson 75
11.3.1 Overview 75
11.3.2 Business Units 78
11.3.3 Geographic Revenue 79
11.3.4 Business Focus 80
11.3.5 SWOT Analysis 81
11.3.6 Business Strategies 81
11.4 Danaher Corporation 82
11.4.1 Overview 82
11.4.2 Business Unit 86
11.4.3 Geographic Presence 86
11.4.4 Business Focus 87
11.4.5 SWOT Analysis 88
11.4.6 Business Strategy 88
11.5 Siemens Healthineers Inc. (Siemens AG) 89
11.5.1 Overview 89
11.5.2 Business Units 92
11.5.3 Geographic Presence 94
11.5.4 Business Focus 94
11.5.5 SWOT Analysis 95
11.5.6 Business Strategy 95
12 Companies to Watch For 96
12.1 Trinity Biotech plc 96
12.1.1 Overview 96
12.1.2 Trinity Biotech plc: Recent Developments 97
12.2 Qiagen N.V. 97
12.2.1 Overview 97
12.2.2 Qiagen N.V.: Recent Developments 97
12.3 BioMerieux S.A. 101
12.3.1 Overview 101
12.3.2 BioMerieux S.A.: Recent Developments 102
12.4 OraSure Technologies' Inc. 103
12.4.1 Overview 103
12.4.2 OraSure Technologies' Inc.: Recent Developments 104
12.5 Instrumentation Laboratory (a Werfen company) 104
12.5.1 Overview 104
12.5.2 Instrumentation Laboratory: Recent Developments 105
12.6 Becton Dickinson and Company 106
12.6.1 Overview 106
12.6.2 Becton dickenson and company: Recent Developments 107
12.7 Nova Biomedical 107
12.7.1 Overview 107
12.7.2 Nova Biomedical: Recent Developments 108
13 Annexure 110
13.1 Abbreviations 110